Fr. 57.50

Development of new quinolines against colorectal carcinoma - DE

English · Paperback / Softback

Shipping usually within 2 to 3 weeks (title will be printed to order)

Description

Read more

Colon cancer is abnormal cells that grow uncontrollably in an organ, resulting in abnormal tissue growth. One of the organs at risk for developing colon cancer cells is the large intestine, or rectum. The current research used computational methods to examine the potential of thirty quinoline compounds as tubulin inhibitors. The main objective of this book is to develop QSAR models to predict the anti-cancer activity of molecules by linking their molecular structures to experimental activities. The models were created using 3D-QSAR, molecular docking, simulation dynamics, and ADMET studies. The results of the research aid researchers and the World Health Organization in identifying molecules that can be developed into effective anti-cancer agents with inhibitory activity.

About the author










Dr. Reda El-Mernissi holds a PhD in chemistry from Moulay Ismail University of Meknes, Morocco. Dr. Reda El-Mernissi is a Qualifying secondary school Physical Chemistry teacher. He has published a number of research articles in various reputed national and international journals and has participated in several conferences on drug design processes.

Product details

Authors Mohammed Aziz Ajana, Mohammed Bouachrine, Reda El-Mernissi
Publisher LAP Lambert Academic Publishing
 
Languages English
Product format Paperback / Softback
Released 27.03.2024
 
EAN 9786207476732
ISBN 9786207476732
No. of pages 52
Subject Natural sciences, medicine, IT, technology > Chemistry > Theoretical chemistry

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.